Catalio Capital Management, LP — 13F Holdings & Portfolio
CIK 1958125 · latest 13F-HR filed 2026-05-15
Catalio Capital Management, LP manages $478.7M in 13F-reported U.S. long-equity assets across 41 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are DNTH (9.82%), BBIO (6.70%), ASND (6.17%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 10 new positions, exited 14, added to 11, and trimmed 16.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$478.7M
Long-equity book
41
Distinct positions
2026-03-31
Filed 2026-05-15
+10 / −14 / ↑11 / ↓16
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- DIANTHUS THERAPEUTICS INC$20.1M +74.6%
- TERNS PHARMACEUTICALS INC$16.0M +289.7%
- ULTRAGENYX PHARMACEUTICAL IN$14.1M +376.8%
- HEARTFLOW INC$6.5M +195.9%
- ASCENDIS PHARMA A/S$4.1M +16.1%
Top Trims
- BOSTON SCIENTIFIC CORP-$15.6M -45.3%
- GILEAD SCIENCES INC-$12.7M -35.7%
- SUPERNUS PHARMACEUTICALS-$9.6M -74.9%
- FRACTYL HEALTH INC-$9.6M -79.2%
- BRISTOL-MYERS SQUIBB CO-$9.4M -27.0%
New Positions
- BRIDGEBIO PHARMA INC$32.1M
- DEFINIUM THERAPEUTICS INC$19.6M
- INCYTE CORP$17.1M
- CORVUS PHARMACEUTICALS INC$13.0M
- VERADERMICS INC$11.0M
Exited Positions
- BRIDGEBIO ONCOLOGY THERAPEUT$31.4M
- ELI LILLY & CO$27.9M
- JOHNSON & JOHNSON$25.0M
- REGENERON PHARMACEUTICALS$23.0M
- INTUITIVE SURGICAL INC$15.4M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $47.0M | 9.82% | 560,308 | SH |
| 2 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $32.1M | 6.70% | 432,014 | SH |
| 3 | ASCENDIS PHARMA A/S | ASND | 04351P101 | $29.5M | 6.17% | 129,111 | SH |
| 4 | BRISTOL-MYERS SQUIBB CO | BMY | 110122108 | $25.5M | 5.33% | 420,727 | SH |
| 5 | SYNDAX PHARMACEUTICALS INC | SNDX | 87164F105 | $24.4M | 5.09% | 1,043,670 | SH |
| 6 | GILEAD SCIENCES INC | GILD | 375558103 | $22.8M | 4.77% | 163,905 | SH |
| 7 | TERNS PHARMACEUTICALS INC | TERN | 880881107 | $21.6M | 4.50% | 409,031 | SH |
| 8 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $19.6M | 4.10% | 1,037,984 | SH |
| 9 | SOLENO THERAPEUTICS INC | SLNO | 834203309 | $19.3M | 4.04% | 577,808 | SH |
| 10 | BOSTON SCIENTIFIC CORP | BSX | 101137107 | $18.8M | 3.92% | 299,318 | SH |
| 11 | ULTRAGENYX PHARMACEUTICAL IN | RARE | 90400D108 | $17.8M | 3.72% | 850,797 | SH |
| 12 | INCYTE CORP | INCY | 45337C102 | $17.1M | 3.58% | 182,101 | SH |
| 13 | CYTOKINETICS INC | CYTK | 23282W605 | $14.2M | 2.97% | 215,501 | SH |
| 14 | NATERA INC | NTRA | 632307104 | $14.2M | 2.96% | 70,907 | SH |
| 15 | CORVUS PHARMACEUTICALS INC | CRVS | 221015100 | $13.0M | 2.73% | 891,933 | SH |
| 16 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $12.3M | 2.57% | 255,379 | SH |
| 17 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $11.9M | 2.48% | 439,041 | SH |
| 18 | EDWARDS LIFESCIENCES CORP | EW | 28176E108 | $11.6M | 2.42% | 144,607 | SH |
| 19 | VERADERMICS INC | MANE | 922967104 | $11.0M | 2.29% | 173,582 | SH |
| 20 | ADAPTIVE BIOTECHNOLOGIES COR | ADPT | 00650F109 | $10.0M | 2.10% | 722,784 | SH |
| 21 | HEARTFLOW INC | HTFL | 42238D107 | $9.8M | 2.05% | 403,588 | SH |
| 22 | KALVISTA PHARMACEUTICALS INC | KALV | 483497103 | $8.6M | 1.79% | 426,551 | SH |
| 23 | UNIQURE NV | QURE | N90064101 | $8.0M | 1.68% | 491,116 | SH |
| 24 | DISC MEDICINE INC | IRON | 254604101 | $7.9M | 1.64% | 122,978 | SH |
| 25 | SEPTERNA INC | SEPN | 81734D104 | $7.1M | 1.48% | 294,360 | SH |
| 26 | ABIVAX SA | ABVX | 00370M103 | $5.3M | 1.10% | 47,193 | SH |
| 27 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $5.1M | 1.07% | 282,954 | SH |
| 28 | ELEDON PHARMACEUTICALS INC | ELDN | 28617K101 | $5.1M | 1.06% | 1,639,816 | SH |
| 29 | KARYOPHARM THERAPEUTICS INC | KPTI | 48576U205 | $5.0M | 1.04% | 897,709 | SH |
| 30 | SUPERNUS PHARMACEUTICALS | SUPN | 868459108 | $3.2M | 0.67% | 62,019 | SH |
| 31 | PROTARA THERAPEUTICS INC | TARA | 74365U107 | $3.0M | 0.63% | 580,024 | SH |
| 32 | PHATHOM PHARMACEUTICALS INC | PHAT | 71722W107 | $2.8M | 0.58% | 247,767 | SH |
| 33 | NEWAMSTERDAM PHARMA COMPANY | NAMS | N62509109 | $2.7M | 0.56% | 83,554 | SH |
| 34 | TYRA BIOSCIENCES INC | TYRA | 90240B106 | $2.6M | 0.54% | 67,285 | SH |
| 35 | IMMUNOCORE HLDGS PLC | IMCR | 45258D105 | $2.5M | 0.53% | 84,352 | SH |
| 36 | FRACTYL HEALTH INC | GUTS | 35168W103 | $2.5M | 0.53% | 5,491,866 | SH |
| 37 | HYPERFINE INC | HYPR | 44916K106 | $1.4M | 0.30% | 1,320,041 | SH |
| 38 | METAGENOMI THERAPEUTICS INC | MGX | 59102M104 | $708.9K | 0.15% | 528,993 | SH |
| 39 | ATAIBECKLEY INC | ATAI | 04650F101 | $696.9K | 0.15% | 196,858 | SH |
| 40 | SENSEI BIOTHERAPEUTICS INC | SNSE | 81728A207 | $463.9K | 0.10% | 14,718 | SH |
| 41 | OUTSET MED INC | OM | 690145206 | $454.2K | 0.09% | 118,279 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $478.7M | 41 | 0001958125-26-000003 |
| 2025-12-31 | 2026-02-17 | $565.8M | 45 | 0001958125-26-000002 |
| 2025-09-30 | 2025-11-14 | $540.9M | 38 | 0001958125-25-000009 |